[Local treatment with diclofenac-Na eyedrops in diseases of the anterior eye segment].
The nonsteroid anti-inflammatory drug (NSAID) diclofenac-sodium, in the galenic form of an eye drop solution (0.1%), has been tested in an open clinical trial in the following indications: episcleritis (30 patients), limbal corneal ulcer (9 patients), hay-fever conjunctivitis and/or conjunctivitis phlyctaenulosa (11 patients). The result of this clinical trial has shown that diclofenac-sodium eye drop solution fulfills all the requirements of a well-tolerated and effective NSAID. The application of diclofenac-sodium eye drop solution (3-5 times daily) resulted in a clear-cut reduction in the use of eye drops containing steroids and its prominent analgesic effect was impressive. Although a slight, transient burning sensation was noticed by a few patients shortly after instillation, no local or systemic adverse reactions were observed.
D000328:Adult; D000368:Aged; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D003320:Corneal Ulcer / Q000188:drug therapy*; D003907:Dexamethasone / Q000627:therapeutic use; D004008:Diclofenac / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D008297:Male; D009883:Ophthalmic Solutions; D012590:Sclera / Q000187:drug effects*
D009883:Ophthalmic Solutions; D004008:Diclofenac; D003907:Dexamethasone
Lokale Behandlung mit Diclofenac-Na-Augentropfen bei Erkrankungen der vorderen Augenabschnitte.